Sign in or create an account to add this stock to your watchlist.
About Lipocine (NASDAQ:LPCN)
Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that is currently in Phase II testing; and LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration. Lipocine Inc. is headquartered in Salt Lake City, Utah.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LPCN
CUSIPN/A
Phone801-994-7383
Debt
Debt-to-Equity Ratio0.52
Current Ratio5.03
Quick Ratio5.04
Price-To-Earnings
Trailing P/E Ratio-1.16
Forward P/E Ratio-1.33
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.78 per share
Price / Book1.56
Profitability
EPS (Most Recent Fiscal Year)($1.05)
Net Income$-20,980,000.00
Net MarginsN/A
Return on Equity-89.14%
Return on Assets-67.72%
Miscellaneous
Employees14
Outstanding Shares21,260,000
Lipocine (NASDAQ:LPCN) Frequently Asked Questions
What is Lipocine's stock symbol?
Lipocine trades on the NASDAQ under the ticker symbol "LPCN."
How were Lipocine's earnings last quarter?
Lipocine (NASDAQ:LPCN) released its quarterly earnings results on Monday, May, 7th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.21) by $0.08. The specialty pharmaceutical company had revenue of $0.43 million for the quarter. View Lipocine's Earnings History.
When is Lipocine's next earnings date?
What price target have analysts set for LPCN?
5 brokerages have issued 1-year price targets for Lipocine's shares. Their predictions range from $2.00 to $38.00. On average, they expect Lipocine's stock price to reach $12.80 in the next year. View Analyst Ratings for Lipocine.
Who are some of Lipocine's key competitors?
Some companies that are related to Lipocine include CytoDyn (CYDY), Northwest Biotherapeutics (NWBO), Ophthotech (OPHT), Columbia Laboratories (JNP), Sesen Bio (SESN), BioLineRx (BLRX), Advaxis (ADXS), KalVista Pharmaceuticals (KALV), KemPharm (KMPH), VIVUS (VVUS), Cumberland Pharmaceuticals (CPIX), Galmed Pharmaceuticals (GLMD), Gemphire Therapeutics (GEMP), Sunesis Pharmaceuticals (SNSS) and Axsome Therapeutics (AXSM).
Who are Lipocine's key executives?
Lipocine's management team includes the folowing people:
- Dr. Mahesh V. Patel Ph.D., Co-Founder, Chairman, Pres & CEO (Age 61)
- Mr. Morgan R. Brown MBA, CPA, Exec. VP, CFO & Corp. Sec. (Age 50)
- Dr. William I. Higuchi Ph.D., Chief Scientific Consultant (Age 87)
- Dr. Anthony DelConte M. D., Chief Medical Director (Age 60)
- Mr. Gregory B. Bass, Exec. VP & Chief Commercial Officer (Age 44)
Has Lipocine been receiving favorable news coverage?
News coverage about LPCN stock has been trending somewhat positive this week, according to Accern. The research group ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Lipocine earned a news impact score of 0.18 on Accern's scale. They also assigned news headlines about the specialty pharmaceutical company an impact score of 47.20 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Lipocine?
Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lipocine's stock price today?
One share of LPCN stock can currently be purchased for approximately $1.22.
How big of a company is Lipocine?
Lipocine has a market capitalization of $26.37 million. The specialty pharmaceutical company earns $-20,980,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Lipocine employs 14 workers across the globe.
How can I contact Lipocine?
Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected]
MarketBeat Community Rating for Lipocine (LPCN)
MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote "Outperform" if you believe LPCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Lipocine (NASDAQ:LPCN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Lipocine in the last 12 months. Their average twelve-month price target is $12.80, suggesting that the stock has a possible upside of 949.18%. The high price target for LPCN is $38.00 and the low price target for LPCN is $2.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.80 | 2.80 | 2.75 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $12.80 | $12.80 | $13.50 | $24.6667 |
| Price Target Upside: | 949.18% upside | 776.71% upside | 621.93% upside | 470.99% upside |
Lipocine (NASDAQ:LPCN) Consensus Price Target History
Lipocine (NASDAQ:LPCN) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Lipocine (NASDAQ:LPCN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Lipocine (NASDAQ LPCN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 11.30%
Institutional Ownership Percentage: 9.71%
Lipocine (NASDAQ LPCN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/29/2017 | Gregory Brooks Bass | Insider | Sell | 3,750 | $3.47 | $13,012.50 | |  |
| 12/29/2017 | Gregory Brooks Bass | Insider | Sell | 3,750 | $3.47 | $13,012.50 | 9,375 | |
| 12/29/2017 | Jeffrey Arvin Fink | Director | Sell | 938 | $3.47 | $3,254.86 | | |
| 12/29/2017 | Mahesh V Patel | CEO | Sell | 6,000 | $3.48 | $20,880.00 | | |
| 12/29/2017 | Mahesh V Patel | CEO | Sell | 6,000 | $3.48 | $20,880.00 | 728,112 | |
| 12/29/2017 | Morgan R Brown | CFO | Sell | 2,813 | $3.47 | $9,761.11 | 26,375 | |
| 12/29/2017 | Morgan R Brown | CFO | Sell | 2,813 | $3.47 | $9,761.11 | | |
| 12/29/2017 | Stephen A Hill | Director | Sell | 1,250 | $3.47 | $4,337.50 | 6,500 | |
| 9/30/2015 | John W Higuchi | Director | Buy | 5,000 | $12.68 | $63,400.00 | 693,382 | |
| 9/30/2015 | Mahesh V. Patel | CEO | Buy | 4,000 | $11.84 | $47,360.00 | 887,632 | |
| 11/25/2014 | Mahesh V Patel | CEO | Buy | 2,000 | $5.10 | $10,200.00 | | |
| 11/24/2014 | Mahesh V Patel | CEO | Buy | 2,000 | $5.45 | $10,900.00 | | |
| 11/19/2014 | Richard Dana Ono | Director | Buy | 4,000 | $5.14 | $20,560.00 | | |
| 11/14/2014 | Mahesh V Patel | CEO | Buy | 2,000 | $5.06 | $10,120.00 | | |
| 11/13/2014 | Mahesh V Patel | CEO | Buy | 2,000 | $5.05 | $10,100.00 | | |
| 11/13/2014 | Stephen A Hill | Director | Buy | 4,000 | $4.95 | $19,800.00 | | |
(Data available from 1/1/2013 forward)
Lipocine (NASDAQ LPCN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | -$0.26 Earnings Per Share Expected for Lipocine (LPCN) This Quarter
www.americanbankingnews.com - May 20 at 9:06 PM |
 | Analysts Expect Breakeven For Lipocine Inc (NASDAQ:LPCN)
finance.yahoo.com - May 17 at 8:22 AM |
| LPCN: Another CRL: Updated Timeline Points to 1Q:19 FDA Response
finance.yahoo.com - May 14 at 5:20 PM |
| Lipocine to Post Q3 2018 Earnings of ($0.22) Per Share, Zacks Investment Research Forecasts (LPCN)
www.americanbankingnews.com - May 14 at 3:06 AM |
| Lipocine (LPCN) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 13 at 9:49 AM |
| Lipocine Expected to Post Q2 2018 Earnings of ($0.22) Per Share (LPCN)
www.americanbankingnews.com - May 11 at 8:35 AM |
| HC Wainwright Analysts Give Lipocine (LPCN) a $3.00 Price Target
www.americanbankingnews.com - May 10 at 7:05 PM |
| Seaport Global Securities Analysts Lower Earnings Estimates for Lipocine (LPCN)
www.americanbankingnews.com - May 10 at 6:51 AM |
 | BRIEF-Lipocine Receives Complete Response Letter For Tlando From US FDA
www.reuters.com - May 9 at 5:33 PM |
 | Lipocine's Regulatory Hiccups Continue: Testosterone Drug Issued Complete Response Letter, Stock Tanks
feeds.benzinga.com - May 9 at 11:17 AM |
| Seaport Global Securities Analysts Cut Earnings Estimates for Lipocine (LPCN)
www.americanbankingnews.com - May 9 at 9:47 AM |
 | Lipocine (LPCN) Receives CRL for TLANDO From FDA
www.streetinsider.com - May 9 at 8:19 AM |
| Lipocine shares drop 38% after FDA fails to approve testosterone replacement therapy
finance.yahoo.com - May 9 at 8:19 AM |
| Lipocine Receives Complete Response Letter for TLANDO From U.S. Food and Drug Administration
finance.yahoo.com - May 9 at 8:19 AM |
| Lipocine (LPCN) Upgraded to "Sell" by ValuEngine
www.americanbankingnews.com - May 8 at 11:26 PM |
| Lipocine (LPCN) Announces Quarterly Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - May 8 at 12:44 PM |
| Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure
www.benzinga.com - May 8 at 8:16 AM |
| BRIEF-Lipocine Announces Q1 Loss Per Share $0.13
www.reuters.com - May 7 at 5:38 PM |
| Lipocine: 1Q Earnings Snapshot
finance.yahoo.com - May 7 at 5:38 PM |
| Lipocine Announces Financial and Operational Results for the First Quarter Ended March 31, 2018
finance.yahoo.com - May 7 at 8:20 AM |
| Form DEFA14A Lipocine Inc.
www.streetinsider.com - May 4 at 8:18 AM |
| Lipocine (LPCN) Expected to Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - May 3 at 6:10 PM |
 | Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Lipocine, Inc ...
globenewswire.com - April 23 at 8:15 AM |
| Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Lipocine, Inc. -- LPCN
finance.yahoo.com - April 23 at 8:15 AM |
| Lipocine (LPCN) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 18 at 8:40 AM |
| Lipocine (LPCN) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - April 11 at 3:58 PM |
| Roth Capital Analysts Give Lipocine (LPCN) a $38.00 Price Target
www.americanbankingnews.com - April 10 at 8:23 PM |
| LPCN: Coming at the FDA Like a Spider Monkey
finance.yahoo.com - April 2 at 5:27 PM |
| Canaccord Genuity Reaffirms "Hold" Rating for Lipocine (LPCN)
www.americanbankingnews.com - March 29 at 9:04 PM |
| Seaport Global Securities Initiates Coverage on Lipocine (LPCN)
www.americanbankingnews.com - March 29 at 12:28 PM |
| Lipocine (LPCN) Stock Rating Lowered by Canaccord Genuity
www.americanbankingnews.com - March 28 at 11:32 PM |
| Lipocine Inc (LPCN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 24 at 8:04 AM |
| Lipocine to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 21 at 8:49 AM |
| Lipocine to Present at the Oppenheimer 28th Annual Healthcare Conference
finance.yahoo.com - March 14 at 8:33 AM |
| Lipocine (LPCN) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - March 13 at 6:22 PM |
| -$0.26 Earnings Per Share Expected for Lipocine Inc (LPCN) This Quarter
www.americanbankingnews.com - March 13 at 12:19 PM |
| Lipocine (LPCN) Issues Quarterly Earnings Results
www.americanbankingnews.com - March 13 at 10:39 AM |
 | Lipocine Announces Financial and Operational Results for the ... - PR Newswire (press release)
www.prnewswire.com - March 12 at 6:39 PM |
| Lipocine Announces Financial and Operational Results for the Fiscal Year Ended December 31, 2017
finance.yahoo.com - March 12 at 9:03 AM |
| Interested In Lipocine Inc (NASDAQ:LPCN)? Here’s What Its Recent Performance Looks Like
finance.yahoo.com - March 6 at 8:15 AM |
| 373,101 Shares in Lipocine Inc (LPCN) Purchased by Prosight Management LP
www.americanbankingnews.com - March 5 at 4:07 PM |
| Lipocine to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 5 at 8:18 AM |
| UPDATE: Empire Asset Upgrades Lipocine Inc (LPCN) to Buy, 'Conceivable Approval on PDUFA'
www.streetinsider.com - February 28 at 6:03 PM |
| UPDATE: Empire Asset Upgrades Lipocine Inc (LPCN) to Buy, 'Conceivable Approval on PDUFA' - StreetInsider.com
www.streetinsider.com - February 28 at 8:18 AM |
| Empire Asset Assigns Penny Stock Lipocine $21 Price Target, Buy Rating
finance.yahoo.com - February 27 at 5:54 PM |
| Lipocine Inc (LPCN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 27 at 9:52 AM |
| Lipocine (LPCN) to Release Earnings on Monday
www.americanbankingnews.com - February 26 at 3:38 AM |
| Lipocine Inc (LPCN) Expected to Post Earnings of -$0.26 Per Share
www.americanbankingnews.com - February 24 at 9:26 AM |
| LIPOCINE INVESTIGATION INITIATED BY FORMER...
www.benzinga.com - February 17 at 8:14 AM |
| LIPOCINE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lipocine Inc. - LPCN
finance.yahoo.com - February 17 at 8:14 AM |
Lipocine (NASDAQ:LPCN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Lipocine (NASDAQ:LPCN) Income Statement, Balance Sheet and Cash Flow Statement
Lipocine (NASDAQ LPCN) Stock Chart for Friday, May, 25, 2018
Loading chart…
